This one has investors everywhere frothing at the mouth — or at least, that’s how it seems from this end of the email queries your friendly neighborhood Gumshoe is receiving about Louis Navellier’s favorite stock. So at the very least, the copywriters at Investorplace (Navellier’s publisher) are awfully good at catching your eye — they […]
Articles
Newsletter ads always sound a little familiar — the same cabal of copywriters are putting together most of these spiels, and they all copy from each other when some new “hook” is found that seems to work to reel in new subscribers. But sometimes it’s a stronger feeling of deja vu than others… and that’s […]
This piece originally ran on November 18, when Louis first started touting this as a must buy “Almost Perfect” stock. Turns out, it was a prescient call this time around and the stock shot up after they raised their guidance when earnings came out late last week. So what’s up now? I haven’t re-done my […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
MEI Pharma (MEIP). It was not hard for me to figure out with the clues he gave, most notably, MEI received FDA fast trac...
The email blast he's been sending out this month for a cancer company treating lymphoma that "could save your life" is M...
I figured out Jovine's April takeover candidate. It's MEI Pharma (MEIP). This company is developing a drug for lymphoma....